A small molecule inhibitor—TAK-981—that selectively inhibits SUMO2 is currently in phase 1/2 clinical trial for Non-Hodgkin lymphoma (NCT04074330) and phase 1b/2 for refractory multiple myeloma (NCT047760180). The gene discussed is SUMO2; the disease is plasma cell myeloma.